Crystacide Cream 1%
Out of date information, search anotherSUMMARY OF PRODUCT CHARACTERISTICS
1 NAME OF THE MEDICINAL PRODUCT
CRYSTACIDE CREAM 1%
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
Active ingredient
Hydrogen peroxide 1.0% (w/w)
1g of cream contains 10mg of hydrogen peroxide at a concentration of 1%.
3 PHARMACEUTICAL FORM
Cream.
4 CLINICAL PARTICULARS
4.1 Therapeutic indications
Crystacide cream is intended for topical application for the treatment of primary and secondary superficial skin infections caused by organisms sensitive to hydrogen peroxide.
4.2 Posology and method of administration
Adults, elderly and children
Crystacide cream is applied 2-3 times daily on the infected skin area. The treatment period should not exceed 3 weeks. A dry film will appear on the skin after application, this can be washed off with water.
Hypersensitivity to the active substance or any of the excipients.
4.4 Special warnings and precautions for use
Contact with the eyes should be avoided. Crystacide Cream should not be used on large or deep wounds and should not be applied to healthy skin. Hydrogen peroxide can bleach fabric.
Salicylic acid is a mild irritant and can cause dermatitis.
Crystacide Cream also contains propylene glycol which may cause skin irritation.
4.5 Interaction with other medicinal products and other forms of interaction
Crystacide cream is incompatible with iodine, permanganates and other stronger oxidising agents.
4.6 Fertility, Pregnancy and lactation
To be used under medical guidance.
4.7 Effects on ability to drive and use machines
Not applicable.
4.8 Undesirable effects
A mild sensation of burning may be experienced for a short time after application.
Not applicable
5 PHARMACOLOGICAL PROPERTIES
5.1 Pharmacodynamic properties
ATC Code: D0 8A Antiseptics and Disinfectants
Hydrogen peroxide is a well-known antiseptic agent, and is effective against a majority of pathogenic micro-organisms.
In-vitro pharmacology studies have shown that hydrogen peroxide has both activity against a wide variety of micro-organisms, and is a potent antibacterial agent with effect against Gram-positive as well as Gram-negative bacteria.
In-vitro studies have shown that the bactericidal activity of Crystacide cream 1% is equal in effect compared with a 1% aqueous solution of hydrogen peroxide, and the duration of action is longer for the cream.
There are no known pathogenic bacteria or fungi that develop resistance to hydrogen peroxide.
5.2 Pharmacokinetic properties
Reports on the rate of absorption, distribution and excretion of hydrogen peroxide after oral administration are sparse. In the absence of stabilising agent, hydrogen peroxide gradually decomposes to oxygen and water. The decomposition is rapid in the presence of the endogenous enzyme catalase or peroxidase.
5.3 Preclinical safety data
There are no pre-clinical data of relevance to the prescriber which are additional to that already included in other sections of the SPC.
PHARMACEUTICAL PARTICULARS
6
6.1 List of excipients
Glyceryl monolaurate Glyceryl monomyri state Macrogol stearate 5000 Propylene glycol Citric acid anhydrous Sodium hydroxide Sulphuric acid, 1M Sodium oxalate Salicylic acid Di sodium edetate Sodium pyrophosphate Sodium stannate Purified water
6.2 Incompatibilities
Iodine, permanganates and other stronger oxidising agents.
6.3 Shelf life
Unopened: 2 years
After first opening the container: 28 days
6.4 Special precautions for storage
Store below 25°C, in a dry place.
6.5 Nature and contents of container
Crystacide cream is filled into polyethylene tubes pigmented with titanium dioxide, and fitted with polypropylene caps. Each tube is subsequently packed in a unit, printed boxboard carton, in pack sizes of 5g, 10g, 25g and 40g.
6.6 Special precautions for disposal
Not applicable.
7 MARKETING AUTHORISATION HOLDER
Reig Jofre UK Limited 10, The Barns Farm Road
Caddsdown Industrial Park Bideford
Devon EX39 3BT United Kingdom
8 MARKETING AUTHORISATION NUMBER(S)
PL 44095/0011
9 DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION
17/01/2006
10 DATE OF REVISION OF THE TEXT
01/07/2015